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Benzodiazepines: 
benefits versus risks
Benzodiazepines act on the central nervous system and can be 
prescribed for various medical conditions. They are usually classified 
by their duration of action. Patients using long-term benzodiazepines 
are at risk of dependence and tolerance. Benzodiazepines may also 
worsen or mask symptoms of depression and may cause cognitive 
and psychomotor impairment. Therefore, benzodiazepines should not 
be prescribed in the absence of a clear indication. When prescribed, 
benzodiazepines should be prescribed in as low a dose as possible 
and long-term patients should be reviewed regularly. 
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Introduction
Benzodiazepines are drugs which 
depress activity in the part of the brain 
which controls emotion by promoting 
the action of a chemical called gamma-
aminobutyric acid (GABA), the major 
inhibitory neurotransmitter in the central 
nervous system, thus preventing excessive 
brain activity that causes anxiety.1 
Benzodiazepines can be prescribed for 
various medical conditions which include 
anxiety, insomnia, alcohol withdrawal, 
seizure control, muscle relaxation and 
to induce amnesia for uncomfortable 
procedures. They can also be given before 
administration of an anaesthetic, e.g. 
prior to surgery. Benzodiazepines act on 
the central nervous system resulting in 
sedation and muscle relaxation, and lower 
anxiety levels.2 Benzodiazepines are usually 
classified by their duration of action as 
indicated in Table 1. 
treatment in patients who would otherwise 
consume illicit benzodiazepines. In 
situations where anxiety is complicated 
by other illnesses such as schizophrenia, 
the risk of dependence may be considered 
acceptable because of the severity of the 
other disorder. Benzodiazepines may also be 
used as adjunctive treatment in the initial 
management of acute mania where sedation 
is a priority.,6 In other instances there is 
much less evidence to support the use of 
benzodiazepines. 
Depression
Depression is not a primary indication 
for prescribing benzodiazepines. 
Benzodiazepines may only be prescribed 
for depression if the latter is accompanied 
by anxiety or severe distress for short-term 
relief when the patient is subject to extreme 
distress. They do not have a specific 
antidepressant effect, and may offer early 
symptomatic relief while antidepressants 
have time to act, or cover the initial 
increase in anxiety that may occur when 
some antidepressants are prescribed. 
Sleep
Benzodiazepines are effective hypnotics 
for the short-term treatment of insomnia7 
if given in sufficient doses.8 Again, they 
should be used intermittently for 2 to  
weeks and at the lowest dose while more 
appropriate long-term treatments are 
instituted, if the problem is long-term.7,8 
Primary causes of insomnia, such as 
depression or substance misuse, should be 
excluded.7 
Anticonvulsant 
and muscle relaxant actions
Benzodiazepines have anticonvulsant 
and muscle relaxant properties. These 
are often valuable, particularly in the 
emergency treatment of epilepsy and the 
management of spasticity or muscle spasms.
Excitement, agitation 
and severe psychotic disturbance 
Patients with excitement, agitation 
and severe psychotic disturbance may be 
prescribed short-term benzodiazepines 
to obtain rapid tranquillisation or as an 
adjunct to their antipsychotic drugs. The 
dose and duration of such treatment needs 
to be monitored closely. 
Uses	of	Benzodiazepines
Anxiety
Benzodiazepines should be prescribed 
primarily for the short-term relief of 
severe anxiety when this is resulting in 
significant distress or problems in social 
functioning. Benzodiazepines are effective 
anxiolytic drugs having an immediate onset 
of action, with their maximum benefit 
shown in the first few weeks of treatment. 
Thus they may offer a period of respite 
whilst other more indicated treatments 
such as antidepressants have time to act. 
Long-term prescription of benzodiazepines 
may be considered desirable in certain 
circumstances when other alternatives are 
considered less appropriate than the use of 
benzodiazepines. This may be in conditions 
such as chronic treatment-resistant 
anxiety or in patients who have confirmed 
dependency and are unable to withdraw 
successfully. Rarely, benzodiazepines may be 
prescribed in the long term as maintenance 
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Risks	of	Benzodiazepines
Dependence
Long-term use of benzodiazepines 
can result in dependence. Dependence on 
benzodiazepines is mainly manifest by 
withdrawal symptoms and even seizures on 
abrupt cessation.2,7 These symptoms may 
sometimes be prolonged and they may be 
hard to distinguish from other anxiety-
related disorders such as panic disorder. 
Symptoms usually develop after three days 
of benzodiazepine cessation, although 
they can appear earlier with short-acting 
varieties.2 Short-acting benzodiazepines 
are more likely to lead to a withdrawal 
syndrome than long-acting ones.9 Therefore, 
to reduce the risk of dependence on 
benzodiazepines, these should not be 
prescribed regularly for longer than one 
month, and ideally be given on as-required 
basis and intermittently every few days.7 
Tolerance
Tolerance can develop with continued 
use of benzodiazepines. Tolerance to the 
hypnotic effects tends to develop rapidly 
whereby patients are initially relieved 
from insomnia, but this is followed by a 
gradual loss of efficacy. Tolerance to the 
anxiolytic effect develops at a slower rate, 
but there is little evidence to indicate that 
benzodiazepines retain their efficacy after 
four to six months of regular use.10,11
Depression
Benzodiazepines may worsen or mask 
symptoms of depression. Consequently 
this may deny the patient the opportunity 
of effective antidepressant medication. 
Moreover it may result in disinhibition 
which may lead to suicide attempts. 
Therefore, a benzodiazepine should only 
be prescribed for a brief concomitant 
period with an effective antidepressant, 
such as a tricyclic antidepressant (TCA) or 
a selective serotonin re-uptake inhibitor 
(SSRI), followed by a clinical review within 
2 weeks. Augmenting an antidepressant 
with another antidepressant should be 
considered for patients whose depression is 
treatment resistant and who are prepared 
to tolerate side effects. However, there is 
insufficient evidence to recommend the 
use of benzodiazepine augmentation of 
antidepressants. 
Misuse
Death rarely results from benzodiazepine 
abuse alone.2 However, a proportion of the 
population may abuse benzodiazepines as 
part of a wider drug and alcohol problem. 
Therefore, doctors should be aware that 
medications they prescribe may fall into the 
wrong hands. Maintenance benzodiazepines 
given to addicts are often used to 
supplement illicit sources. 
Cognitive impairment
Benzodiazepines may cause cognitive 
impairment, mainly involving memory 
disturbance and subtle learning impairment. 
Cognitive impairment may not allow 
patients to make an optimum response 
to a situation which they may be facing. 
In cases of loss or bereavement the 
psychological adjustment to this trauma 
may also be inhibited by benzodiazepines. 
On the other hand, short-term symptomatic 
relief of benzodiazepines may aid the 
natural healing process.7
Disinhibition	
Extreme caution should be used in 
prescribing benzodiazepines in patients 
with severe personality disorders. Studies 
have shown that use of benzodiazepines in 
such patients may increase the incidence of 
suicidal behaviour. Moreover, combination 
with alcohol is common and dangerous. The 
use of benzodiazepines in this category of 
patient may facilitate aggressive behaviour 
both towards the self and others.7 
Psychomotor impairment
Higher doses of benzodiazepines may 
cause psychomotor impairment which 
could affect activities such as driving and 
operating machinery. Therefore, when 
starting benzodiazepines a low dose should 
be given initially. Furthermore there is a 
particular problem with the elderly, who 
are more sensitive to benzodiazepine 
effects and who metabolize long-acting 
benzodiazepines slowly. There is a build-up 
of drug over time and this may result in 
chronic intoxication and falls resulting in 
fractures.7
Sleep
Studies have shown that patients who 
have taken benzodiazepines for period 
in excess of -6 months have become, 
inadvertently, dependent and experience 
withdrawal insomnia.8 Psychiatric 
disorders such as anxiety, depression and 
abuse of drugs and alcohol are common 
causes of chronic insomnia. Chronic 
insomnia is rarely benefited by hypnotics 
such as benzodiazepines. Instead the 
underlying psychiatric complaint should 
be treated.12 Therefore, the Committee on 
Safety of Medicines (CSM) suggests that 
benzodiazepines should be used to treat 
insomnia only when it is severe, disabling, 
or subjecting the individual to extreme 
distress.12
Recommendations
Studies still show a continued 
high prevalence of benzodiazepine use 
despite the well known adverse effects 
Table	2:	Withdrawal	guideline	for	patients	on	benzodiazepines12
1. Transfer patient to equivalent daily dose of diazepam preferably taken at night
2. Reduce diazepam dose every 2-3 weeks in steps of 2 or 2.mg; if withdrawal symptoms 
occur, maintain this dose until symptoms improve
3. Reduce dose further, if necessary in smaller steps (diazepam 00 micrograms to 2.mg)
. Stop completely; time needed for withdrawal can vary between patients
Table	1:	Duration	of	action	of	benzodiazepines3
Ultra-short	acting Short-acting
t½	less	than	6	hours
Intermediate-acting
t½	6-24	hours
Long-acting
t½	greater	than	24	hours
Midazolam Zopiclone
Zolpidem
Alprazolam
Lorazepam
Temazepam
Diazepam
Flurazepam
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of benzodiazepines discussed above and 
the availability of safer and effective 
alternatives. From these studies it was 
shown that primary care physicians are 
averse to addressing the public health 
problem of benzodiazepine overuse 
in the elderly.13 Researchers found 
contraindications, including falls and 
depression, in 7 per cent of those 
given benzodiazepines.1,1 Therefore, 
repeat prescriptions could be a cause 
of benzodiazepine overuse.16 Doctors’ 
attitudes generally conflict with practice 
guidelines and they complain of a lack 
of training in constructive strategies to 
address this problem.13 Hence, the following 
recommendations are being made:
1. Benzodiazepines should not be prescribed 
in the absence of a clear indication.
2. Benzodiazepines should be prescribed 
in as low a dose as possible to afford 
symptomatic relief7 and patients should 
be advised of the risk of dependence 
associated with long-term use.8 Patients 
should also be advised to obtain their 
prescriptions for benzodiazepines from 
the same doctor, wherever possible, 
so that risk of dependence may be 
monitored.8 In addition patients should 
be advised on possible adverse effects 
such as drowsiness, which may have an 
effect on driving or operating machinery.9
3. When prescribing benzodiazepines long-
term patients should be reviewed. This 
should include a review of the indication 
for continued use of the benzodiazepine, 
the dosage regime and any possible side-
effects. 
. Benzodiazepine reduction and cessation 
should be with the patient’s consent and 
co-operation. 
. Even after the short-term use of 
benzodiazepines, it is advised that a 
tapering-off regime (i.e. at least 2 weeks 
at reduced dosage) should be used to 
minimize rebound phenemona. After longer 
use this reduction period may have to be 
extended, sometimes to several months in 
extreme cases.7 
6. Benzodiazepine tapering-off may be 
facilitated by changing patients to long 
half-life medications, such as diazepam, 
and then slowly reducing the dose. A 
suggested withdrawal guideline for 
patients who have difficulty in stopping 
benzodiazepines is shown in Table 2.
Conclusion
Benzodiazepines may be prescribed safely 
and effectively for the short-term treatment 
of anxiety and insomnia and can also be used 
for some forms of epilepsy and spasticity. 
Dependence is now recognized as a significant 
risk in patients receiving treatment for longer 
than one month and is often extremely 
difficult to treat. Therefore, doctors have to 
examine the benefit:risk ratio of continued 
prescription in each individual early in 
treatment, so that if dependence occurs, it is 
anticipated by doctor and patient alike.2  
•	 When a patient complains of insomnia one should first consider non-pharmacological 
measures, such as avoiding caffeine-containing products late at night, exercise during 
the day, identify and avoid, if possible, the cause of the insomnia.
•	 Benzodiazepines should only be prescribed for insomnia for short-term use in 
accordance with their licensed indications.
•	 If insomnia continues to be a problem, one may opt to prescribe a short-term non-
benzodiazepine hypnotic, for a maximum of 2 weeks’ duration.
•	 Whilst withdrawing benzodiazepines, the patient will need other supportive measures 
such as counseling and relaxation techniques.
•	 If a patient is benzodiazepine and opioid dependent, both drugs would not normally 
be withdrawn simultaneously. The opioid dose is kept stable until full withdrawal from 
the benzodiazepine has been attained.
Practice	Points
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